

Amendments to the Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) An agent for prevention of and/or treatment for vasospasm accompanying a bypass operation, which comprises as an active ingredient either a compound represented by the following general formula

(I):

[Chem 1]




where R¹ represents a hydrogen atom or a hydroxyl group, or an acid addition salt or hydrate thereof.

2. (Original) The agent for prevention of and/or treatment for vasospasm accompanying a bypass operation according to Claim 1, wherein the bypass operation comprises coronary artery bypass grafting.

3. (Currently Amended) The agent for prevention of and/or treatment for vasospasm accompanying a bypass operation according to Claim 1 or 2, wherein the vasospasm comprises vasospasm which does not respond to a calcium antagonist and/or a nitro-compound.

4. (Currently Amended) The agent for prevention of and/or treatment for vasospasm accompanying a bypass operation according to Claim 1 ~~any one of Claims 1 to 3~~, wherein the vasospasm occurs in a region which differs from an anastomosis region.

5. (New) A method for prevention of and/or treatment for vasospasm accompanying a bypass operation, which comprises administering an effective amount of an agent to a person in need, wherein the agent comprises as an active ingredient either a compound represented by the following general formula (I):



in which R¹ represents a hydrogen atom or a hydroxyl group, or an acid addition salt or hydrate thereof.

6. (New) A method according to Claim 5, wherein the bypass operation is coronary artery bypass grafting.

7. (New) A method according to Claim 5, wherein the vasospasm is the one that does not respond to a calcium antagonist and/or a nitro-compound.

8. (New) A method according to Claim 5, wherein the vasospasm occurs in a region which differs from an anastomosis region.